ROR1 heterogeneity in mantle cell lymphoma: what 15 flow-cytometry cases show

ROR1 is not uniformly expressed by primary MCL

Wang, Rao, Lobello and colleagues published Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms in Leukemia on 14 October 2026 (DOI: 10.1038/s41375-026-03169-w). Using CD19 and CD5 to identify mantle cell lymphoma (MCL) cells by flow cytometry, the investigators found variable ROR1 staining in 15 primary patient samples: 5 minimal/undetectable, 7 dim and 3 moderate.

The authors documented increased ROR1 signal in a second blood sample from one patient approximately one year later, and a different intensity between blood and lymph node specimens in another. In a separate immunohistochemistry set, 66 tissue samples from 42 different MCL cases comprised 13 negative, 32 weak and 21 moderate/strong ROR1 observations; 13 of 20 multiply sampled patients varied between samples. Tissue IHC scoring and fluorescence intensities from flow are not interchangeable analytical scales.

Mechanistic observations

ROR1 silencing or knockout in experimental MCL models reduced cell growth and survival and affected cell-cycle, metabolic and phosphorylation programs. Long-term exposure to ibrutinib induced ROR1 in a cell line; related animal models showed altered drug sensitivity. These are mechanistic findings, not prospective clinical predictions.

Primary source: Wang et al., Leukemia (2026).

Methodological and clinical limits

Only 15 primary samples are described for flow categories; the case numbers are not population prevalence estimates, reference intervals or validated cut-offs for a clinical ROR1 assay. The limited patient paired examples do not prove that serial ROR1 testing improves outcomes. Flow and IHC categories cannot be numerically combined. Functional inhibition was tested in model systems; it does not establish ROR1 expression as a treatment-selection biomarker or justify changes in clinical therapy.

Antibody clone and epitope, fluorochrome, background, instrument sensitivity, specimen processing and gating can shift apparent dim/negative classification. Cross-platform harmonisation and ROR1 calibrator thresholds are not established in this study. This is original research, not a new CE-IVD/FDA approval. The paper's CC BY-NC-ND 4.0 licence does not independently authorise commercial reuse or adapted source figures; Figure 1 permission is requested and pending.

Why it matters to a flow laboratory

A candidate therapeutic antigen is not necessarily binary or stable. Laboratory reports should distinguish the sample type and timing, quantify staining relative to validated background and document any phenotypically distinct subsets. ROR1 detection among CD19+CD5+ MCL cells may vary between patient, tissue compartment and time; without validated reference methods, negative/dim/moderate bins should remain descriptive.

Daily Learning Pill — antigen density is not antigen positivity

Target presence, surface density and functional accessibility are separate questions. Dim staining depends on analytical resolution and antibody–antigen affinity, while biological target density may evolve under treatment pressure. Before treating a dim population as negative, review controls, the gating denominator, autofluorescence and detector settings. Academy reuse: Lymphoma Immunophenotyping → target heterogeneity, longitudinal comparisons and dim-marker QC.